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2-(Trimethylsilyl)ethoxymethyl (SEM)During the course of a research program aimed at identifying novel antileishmanial compounds, a multi-
gram synthesis of N-(trans-4-((4-methoxy-3-((R)-3-methylmorpholino)-1H-pyrazolo[3,4-d]pyrimidin-6-
yl)amino)cyclohexyl)-2-methylpropane-1-sulfonamide ((R)-1) was required. This letter describes opti-
misation of the reaction conditions and protecting group strategy for a key Buchwald-Hartwig coupling,
delivering the required quantities of (R)-1, as well as further compounds in the series.
Crown Copyright  2019 Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
During the course of a research program aimed at identifying
novel antileishmanial compounds, we discovered a series of N1-
(1H-pyrazolo[3,4-d]pyrimidin-6-yl)cyclohexyl-1,4-trans-diamine
compounds that led to GSK3186899/DDD853651 being selected as
a pre-clinical development candidate for the treatment of visceral
leishmaniasis (Scheme 1) [1,2]. During the lead optimisation pro-
cess, the chemistry team became interested in compound (R)-1
due to the orientation of a 4-methoxypyrimidyl substituent along-
side a 3-methylmorpholine in the 3-position of the pyrazole ring.
Whilst these groups could be introduced individually in a relatively
straightforward manner (e.g. 3-methylmorpholine with no meth-
oxy (R)-2 or a methoxy substituent and an unsubstituted morpho-
line 3, Scheme 1) incorporating both substituents into a single
compound proved to be synthetically challenging.
The synthetic strategy chosen is highlighted in Scheme 2, start-
ing from 3-bromo-4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine 8;
which involved protection of the pyrazole NAH followed by
sequential displacement of the three halides of 8. The next steprequired a Buchwald-Hartwig coupling using 3-methylmorpholine,
where there are few examples in the literature [3], particularly
when coupled with a sterically hindered partner such as 4. Herein,
we describe the development of the Buchwald-Hartwig coupling
which enabled the delivery of multi-gram quantities of (R)-1, with
sufficiently high purity for 7 day rodent toxicology evaluation.
Within the medicinal chemistry program, analogues with less
sterically hindered morpholines, such as 10a and 11a (Scheme 3),
were synthesised via standard Buchwald-Hartwig coupling condi-
tions in reasonable yields (48–75%) [2,4]. However, when these
conditions were applied to the more sterically hindered 3-methyl-
morpholine of interest (working initially on the racemate), only
around 20% of product was visible by LCMS in the reaction mixture
after heating at reflux overnight, and pure compound could not be
isolated from the crude reaction mixture.
Because of this poor yield, an alternative route to the more ster-
ically hindered compounds was investigated. This was based on
the alternative retrosynthesis in Scheme 4. The key step would
be to construct the pyrazole ring via activation and cyclisation of
an appropriate amide such as 13, avoiding the need for the chal-
lenging Buchwald-Hartwig coupling. This cyclisation was success-
fully used for the synthesis of analogues without a 4-
methoxypyrimidyl substituent through generation and cyclisation
of the thioamide [2]. However in this case, cyclisation did not occur
Scheme 1. A selection of N-1-(1H-pyrazolo[3,4-d]pyrimidin-6-yl)cyclohexyl-1,4-trans-diamine compounds of interest.
Scheme 2. Retrosynthesis of (R)-1.
Scheme 3. Synthesis of less sterically hindered analogues 10a and 11a.
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Table 1
Effect of alternative conditions on the Buchwald-Hartwig coupling to give 16a.
Catalyst Solvent Base Phosphine 16ae 4ae 17ae 18ae
Pd2dba3 Dioxane Cs2CO3 Xantphos 5 16 50 –
Xantphosa 7 45 30 –
RuPhos 4 52 27 –
KHMDS Ruphos 54 – – –
DME Cs2CO3 Xantphos 6 23 49 –
RuPhos 19 21 40 –
tBuONa BINAP 0 – – 53
DPEPhos 0 – – 45
Toluene Cs2CO3 RuPhos 9 60 25 –
Pd(OAc)2 Dioxane Cs2CO3 Xantphosb 22 – 51 –
Xantphosa 17 43 – –
tBuOK Xantphosa 21 24 33 –
KHMDS Ruphosc 52 – – –
DME tBuONa SPhos 0 50 5 25
tBuXPhos 0 34 – 25
2-(dicyclohexylphosphino)biphenyl 0 20 – 56
K3PO4 SPhos 0 68 17 8
Brettphos 0 58 30 10
Cs2CO3 Ruphos 0 16 40 –
Toluene Cs2CO3 Xantphos 0 23 18 –
RuPhos 0 15 9 –
tBuONa BINAPd 0 28 – 39
Reactions were carried out on 50 mg scale using 4a, 5 mol% catalyst, 3.5 eq. base, 5 eq. racemic 3-methylmorpholine and 10 mol% ligand.
a 10 mol% catalyst, 2.8 eq. base, 10 eq. racemic 3-methylmorpholine and 12 mol% ligand.
b 10 mol% catalyst, 2.8 eq. base, 5 eq. racemic 3-methylmorpholine and 12 mol% ligand.
c 5 mol% catalyst, 1.0 eq. base, 5 eq. racemic 3-methylmorpholine and 10 mol% ligand.
d 10 mol% catalyst, 3.0 eq. base, 5 eq. racemic 3-methylmorpholine and 10 mol% ligand.
DME is dimethoxyethane. Crude reaction mixtures were analyzed by LCMS to determine the relative percentages of starting material, product and side-products.
e % by LCMS.
Scheme 4. Alternative retrosynthesis of 1.
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Table 2
Effect of alternative protecting groups to give 1.
Protecting Group (a) THP (b) PMB (c) SEM
Synthesis of 7 from 8 (protection of the pyrazole NAH) (%
yield)
76% 17% 98%
Cross-Coupling (4 to 16, % yield) 18% 39% 53%
Cross-Coupling Conditionsa Pd2dba3 (7.5 mol%)
Ruphos (15 mol%)
KHMDS (3 eq.)3-
Methylmorpholine
(10 eq.)
Pd2dba3 (5 mol%)
Ruphos (10 mol%)
KHMDS (2 eq.)3-
Methylmorpholine
(10 eq.)
Pd2dba3 (10 mol%)
Ruphos (20 mol%)
KHMDS (2 eq.)3-
Methylmorpholine
(10 eq.)
Purification of the Buchwald product Column chromatography  2 Column chromatography  1
Purity 90%
Column chromatography  1
Purity >99%
Deprotection Conditions HCl/MeOH TFA AcCl/MeOH
Deprotection (% yield) 84% 96% 70%
a Best conditions for each protecting group is shown.
Table 3
A range of compounds formed utilising the optimised Buchwald-Hartwig coupling
conditions.
Compound PG Cross-
coupling
(g), %
isolated
yield
(S)-1 SEM 12.7 g,
50%
19 THP 1 g, 13%
(R)-20 SEM 5 g, 64%
(S)-20 SEM 5 g, 62%
21 THP 1.4 g, 12%
22 THP 0.75 g,
12%
23 THP 0.83 g,
18%
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groups being observed.
Because the alternative route proved unsuccessful, we returned
to the initial Buchwald-Hartwig coupling route (Scheme 2) and
undertook an examination of all the components of the reaction:
palladium source, ligand, base and solvent. The intent was to iden-
tify a set of conditions that could deliver at least 100 mg of final
compound.
Table 1 highlights a selection of the conditions tested, demon-
strating the range of variables assessed and that the majority of
conditions gave poor results. Starting material 4a was detected
by liquid chromatography–mass spectrometry (LCMS) in most
cases, alongside two major byproducts: debrominated starting
material 17a and demethylated starting material 18a (particularly
when using sodium tert-butoxide or potassium triphosphate as a
base). Where product 16awas detected, the conversion was gener-
ally poor (0–23%). The choice of base appeared to be a key factor, as
potassium hexamethyldisilazide (KHMDS, a strong non-nucle-
ophilic base) gave significant improvements in conversion (52%
by LCMS) with no evidence of remaining 4a or the byproducts
17a and 18a. Cesium fluoride (a non-nucleophilic and less steri-
cally hindered base) gave no conversion to product with only start-
ing material detected, presumably due to its lower base strength
compared to KHMDS.
Using the identified KHMDS conditions on larger scale (1 g)
delivered 190 mg (18% isolated yield) of 16a, which was subse-
quently tetrahydropyran (THP) deprotected to give 1.
Although these conditions delivered sufficient compound for
early profiling, our continued interest in (R)-1 required us to fur-
ther optimize the challenging cross-coupling for a multi-gram
and high-purity synthesis. We therefore undertook further refine-
ment of the different variables of the reaction. In order to increase
the reactivity of the palladium source, various palladacycles were
investigated [5,6], based on reports of significant improvements
to Buchwald-Hartwig couplings. Unfortunately, in all cases tested,
no improvement was observed. Moreover, 2nd Generation Buch-
wald-Hartwig ligands (e.g. JohnPhos or SPhos) [7], 3rd (e.g. Brett-
Phos, tBuXPhos, Xantphos) [7] and 4th generation ligands (e.g.
Josiphos) [8,9] also failed to improve product formation. Investiga-
tion of other reaction variables including the loading of the palla-
dium catalyst added, the ratio of catalyst to phosphine ligand,
reaction temperature (reduced to 80 C) and solvent (DME, n-buta-
nol, toluene, propylene glycol, 1,3-dimethyl-2-imidazolidinone
R.F. Velasco et al. / Tetrahedron Letters 60 (2019) 1243–1247 1247(DMI) or dioxane); all resulted in little improvement. Varying the
number of equivalents of 3-methylmorpholine was observed to
have some influence on yield, whereby increasing to 10 equiva-
lents increased the isolated yield to 29% when other variables were
kept the same.
This examination of reaction conditions gave a broad coverage
of the standard conditions used in Buchwald-Hartwig couplings
with limited impact on yields; so finally, the effect of the protect-
ing group on the coupling was examined. This proved to have a
major impact on the feasibility of the cross-coupling. The original
THP protecting group was replaced with either p-methoxybenzyl
(PMB) or 2-(trimethylsilyl)ethoxymethyl (SEM). Attempts were
also made to protect the NAH with tosyl, but this proved challeng-
ing to introduce and was not further pursued. After a small amount
of optimization of the number of equivalents of the various
reagents, both PMB and SEM gave a significant increase in the iso-
lated yield of the cross-coupling (i.e. PMB [39%] and SEM [53%]
compared to THP [18%]) (Table 2).
The final step of the synthesis involved removal of the protect-
ing group, the results of which are summarized in Table 2. Stan-
dard SEM deprotection using tetra-nbutylammonium fluoride
(TBAF) gave poor yields, whereas the use of acetyl chloride in
methanol, after optimisation of the reaction conditions, gave a sig-
nificant improvement. Also, when considering the overall reaction
scheme, including introduction and removal of protecting group,
yield of cross-coupling and ease of purification, SEM was deter-
mined to be the most favourable group on all counts. Therefore,
with a set of optimised conditions in hand, the route was scaled
up. The coupling was thus carried out on 35 g of 4c together with
(R)-3-methylmorpholine delivering 16.91 g of (R)-16c, an isolated
yield of 47%. Subsequent deprotection gave 9.26 g of high purity
(R)-1 in an isolated yield of 70% and 100% ee, demonstrating that
no racemisation occurred during synthesis.
Finally, the coupling conditions developed were applied to a
number of different substrates, as highlighted in Table 3. This fur-
ther highlighted that the conditions could be used to deliver a wide
range of compounds to the medicinal chemistry program, and also
that the use of SEM as a protecting group (50–64% yield) gave sig-
nificantly better results than THP (12–18% yield).
Conclusion
In summary, we required a suitable synthetic route to deliver
multi-gram quantities of (R)-1, which involved the Buchwald-
Hartwig coupling of a hindered 3-bromo-1H-pyrazolo[3,4-d]
pyrimidine with 3-methylmorpholine. Optimisation of both the
reaction conditions and the protecting group led to the use of
RuPhos as catalyst, KHMDS as base and SEM as the optimal pro-tecting group. These conditions were then utilized to deliver more
than 9 g of (R)-1 in high purity, as well as being applied to the syn-
thesis of further compounds in the series.
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